- The P-III ATLAS (n= 616) & FLAIR (n= 566) studies involve assessing of Rilpivirine + Cabotegravirin vs oral HIV therapies in virally suppressed HIV patients
- The ATLAS (NCT02951052) & FLAIR (NCT02938520) studies resulted in meeting its 1EPs i.e, plasma HIV-1 RNA ≥50 copies per milliliter (c/mL) & patients with virologic failure, non-inferior to Triumeq respectively @48wks.
- Janssen’s Rilpivirine & and ViiV Healthcare’s Cabotegravir (q4w, inj.) is a long-acting combination therapy codeveloped under Jan,2016 agreement b/w the companies
Click here to read full press release/ article | Ref: Janssen | Image: Law